NLC as a potential carrier system for transdermal delivery of forskolin*

Lasoń, Elwira; Sikora, Elżbieta; Miastkowska, Małgorzata; Escribano, Elvira; García-Celma, María José; Solans, Conxita; Llinàs, Meritxell; Ogonowski, Jan

doi:10.18388/abp.2018_2554

Cited by 10 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DXI-NLC was produced using the high-shear hot homogenization technique [ 57 ]. In brief, the lipid phase was prepared by melting DXI, beeswax and Miglyol 812.…”

Section: Methodsmentioning

confidence: 99%

Novel Strategies against Cancer: Dexibuprofen-Loaded Nanostructured Lipid Carriers

Thiruchenthooran

Świtalska

Bonilla

et al. 2022

IJMS

View full text Add to dashboard Cite

The aim of this work was to design innovative nanostructured lipid carriers (NLCs) for the delivery of dexibuprofen (DXI) as an antiproliferative therapy against tumoral processes, and overcome its side effects. DXI-NLC samples were prepared with beeswax, Miglyol 812 and Tween 80 using high-pressure homogenization. A two-level factorial design 24 was applied to optimize the formulation, and physicochemical properties such as particle size, zeta potential, polydispersity index and entrapment efficiency were measured. Optimized parameters of DXI-NLCs exhibited a mean particle size of 152.3 nm, a polydispersity index below 0.2, and high DXI entrapment efficiency (higher than 99%). Moreover, DXI-NLCs provided a prolonged drug release, slower than the free DXI. DXI-NLCs were stable for 2 months and their morphology revealed that they possess a spherical shape. In vitro cytotoxicity and anticancer potential studies were performed towards prostate (PC-3) and breast (MDA-MB-468) cancer cell lines. The highest activity of DXI-NLCs was observed towards breast cancer cells, which were effectively inhibited at 3.4 μM. Therefore, DXI-NLCs constitute a promising antiproliferative therapy that has proven to be especially effective against breast cancer.

show abstract

“…DXI-NLC was produced using the high-shear hot homogenization technique [ 57 ]. In brief, the lipid phase was prepared by melting DXI, beeswax and Miglyol 812.…”

Section: Methodsmentioning

confidence: 99%

Novel Strategies against Cancer: Dexibuprofen-Loaded Nanostructured Lipid Carriers

Thiruchenthooran

Świtalska

Bonilla

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Epidermal and dermal layers were manually separated using tweezers. CP was extracted in 10 ml methanol by sonication of each skin layer, and extracted samples were assayed for CP concentration using UV spectroscopy at 239 nm 14 .…”

Section: Ex-vivo Diffusion Studymentioning

confidence: 99%

Untitled

2019

IJPSR

View full text Add to dashboard Cite

The aim of the present work was to develop and evaluate the potential of nanostructured lipid carriers (NLCs) loaded with Clobetasol-17-propionate (CP) as a new approach for the topical treatment of psoriasis. CP-loaded NLCs were prepared by melt emulsification and ultra-sonication method and optimized using 3 3 full factorial designs (Design-Expert software 11.0), by using solid lipid (compritol ATO 888) and liquid lipid (oleic acid) and Tween 80 as a surfactant. Drug loaded NLCs were evaluated for various parameters like particle size, surface charge, polydispersity index, entrapment efficiency, surface morphology, thermal analysis, in-vitro drug release through the skin (Franz diffusion cell), drug deposition study and stability. The optimized formulation has a particle size of 91.2 ± 2.37 nm, the zeta potential of -34.7 ± 1.49 mV, polydispersity index of 0.173 ± 0.035 and entrapment efficiency of 85.4 ± 2.89%. Release study demonstrated prolonged CP release from NLCs following Higuchi release kinetics with r 2 = 0.9838, while pure CP suspension showed quicker drug release obeying zero-order kinetics with r 2 value of 0.9904. Skin permeation study of CP loaded SLNs suspension showed prolonged drug release up to 24 h. The maximum ex-vivo drug deposition was obtained after developing the drug into NLCs (51.23 µg/ml) when compared to the pure drug (18.34 µg/ml). The prepared NLCs based formulation has proved to be a promising carrier system for the treatment of psoriasis.

show abstract

“…FSK is poorly soluble in water, where the solubility in water is 0.2 mM [8]. There are several developments of delivery systems, including: emulsion [9], nanoemulsion [10] and nanostructured lipid carrier (NLC) [11]. The three delivery systems contained 0.075% w/v FSK.…”

Section: Introductionmentioning

confidence: 99%

Diffusion and Lipolysis Test on Forskolin Microemulsion Gel

Nafiah¹,

Sumirtapura²,

Darijanto³

et al. 2023

jrp

View full text Add to dashboard Cite

Forskolin is a labdane diterpene that acts as lipolysis, while microemulsion is a delivery system that works as a penetration enhancer at topical application. This study aims to determine the diffusion profile, lipolysis test and skin histology of FSK microemulsion gel applied topically. The diffusion test used Franz cell, while lipolysis activity was carried out on 42 mice which were divided into 7 groups consisting of 6 groups given high fat-fed and 1 group given standard fed as normal control. The six groups were: A1 gel, A1 gel used twice a day, A1 gel base, emulgel, slimming gel product, and control with high fed-fat. The results showed that the A1 microemulsion formula and A1 gel were able to diffuse around 36.81±2.08% and 18.05±0.32% for 6 hours of observation, respectively. Statistical analysis using the least significant difference in body weight changes gave the result that gel A1 twice a day reduced body weight by -3.81 ± 3.17% with p < 0.01 against the control, whereas in the ex vivo lipolysis test it released glycerol levels of 15.99±1.55 nmol/hour with p < 0.05 to control. Histological observations showed that topical application of A1 gel formula showed lysis of lipids in the hypodermis. From the results of this study, microemulsions can deliver forskolin to adipose tissue, thereby forskolin can act as a lipolytic agent.

show abstract

NLC as a potential carrier system for transdermal delivery of forskolin*

Cited by 10 publications

References 32 publications

Novel Strategies against Cancer: Dexibuprofen-Loaded Nanostructured Lipid Carriers

Novel Strategies against Cancer: Dexibuprofen-Loaded Nanostructured Lipid Carriers

Untitled

Diffusion and Lipolysis Test on Forskolin Microemulsion Gel

Contact Info

Product

Resources

About